TGTX Capital Stock from 2010 to 2025

TGTX Stock

USD 42.66 0.00 0.00%

TG Therapeutics Capital Stock yearly trend continues to be fairly stable with very little volatility. Capital Stock will likely drop to about 146.1 K in 2025. Capital Stock is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. View All Fundamentals

Capital Stock

First Reported

2010-12-31

Previous Quarter

156 K

Current Value

146.1 K

Quarterly Volatility

31.1 K

Credit Downgrade

Yuan Drop

Covid

Check TG Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TG Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 195.5 K, Interest Expense of 25.2 M or Total Revenue of 345.5 M, as well as many indicators such as Price To Sales Ratio of 12.63, Dividend Yield of 4.0E-4 or PTB Ratio of 20.65. TGTX financial statements analysis is a perfect complement when working with TG Therapeutics Valuation or Volatility modules.

Check out the analysis of TG Therapeutics Correlation against competitors.

For more information on how to buy TGTX Stock please use our How to Invest in TG Therapeutics guide.

Latest TG Therapeutics' Capital Stock Growth Pattern

Below is the plot of the Capital Stock of TG Therapeutics over the last few years. It is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. TG Therapeutics' Capital Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in TG Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Capital Stock

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Capital Stock

Timeline

TGTX Capital Stock Regression Statistics

	Arithmetic Mean	109,259
	Geometric Mean	105,344
	Coefficient Of Variation	28.48
	Mean Deviation	28,449
	Median	84,000
	Standard Deviation	31,119
	Sample Variance	968.4M
	Range	72K
	R-Value	0.89
	Mean Square Error	223.8M
	R-Squared	0.78
	Slope	5,788
	Total Sum of Squares	14.5B

TGTX Capital Stock History

	2025	146.1 K
	2024	156 K
	2023	151 K
	2022	146 K
	2021	143 K
	2020	141 K
	2019	109 K

Other Fundumenentals of TG Therapeutics

Issuance Of Capital Stock

TG Therapeutics Capital Stock component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Total Liab	Total Current Assets	Net Receivables	Accounts Payable	Common Stock	Property Plant Equipment	Short Term Investments	Long Term Debt	Short Term Debt	Current Deferred Revenue	Intangible Assets	Net Tangible Assets	Good Will	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Treasury Stock	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.11	-0.32	-0.81	0.82	1.0	0.7	0.65	-0.05	0.7	0.78	0.75	0.56	0.16	-0.35	0.66	0.59	0.64	0.9	-0.47	-0.39	-0.08	0.55	0.92	0.92	0.87
Total Stockholder Equity	0.11		0.0	0.33	0.04	0.15	0.28	0.06	-0.04	-0.31	0.18	0.03	0.15	-0.19	0.08	0.01	0.04	-0.32	-0.23	0.22	0.14	-0.48	0.28	0.15	0.19	-0.26
Net Debt	-0.32	0.0		0.05	0.22	-0.31	0.42	0.04	0.06	-0.41	0.24	0.37	-0.9	0.1	0.14	-0.9	0.04	0.3	-0.15	0.0	0.22	-0.17	-0.87	-0.49	-0.45	-0.15
Retained Earnings	-0.81	0.33	0.05		-0.78	-0.8	-0.62	-0.75	0.03	-0.75	-0.82	-0.77	-0.27	-0.19	0.38	-0.36	-0.57	-0.88	-0.98	0.5	0.46	0.03	-0.2	-0.69	-0.69	-0.97
Total Liab	0.82	0.04	0.22	-0.78		0.82	0.91	0.69	-0.15	0.49	0.9	0.95	0.03	0.31	-0.39	0.18	0.73	0.85	0.82	-0.37	-0.45	-0.08	0.03	0.61	0.62	0.76
Total Current Assets	1.0	0.15	-0.31	-0.8	0.82		0.72	0.66	-0.05	0.69	0.79	0.75	0.57	0.16	-0.33	0.65	0.59	0.62	0.89	-0.46	-0.38	-0.12	0.56	0.92	0.92	0.86
Net Receivables	0.7	0.28	0.42	-0.62	0.91	0.72		0.59	0.01	0.29	0.88	0.96	-0.1	0.2	-0.16	-0.03	0.57	0.71	0.65	-0.4	-0.14	-0.27	-0.07	0.52	0.56	0.62
Accounts Payable	0.65	0.06	0.04	-0.75	0.69	0.66	0.59		-0.15	0.5	0.81	0.64	0.26	0.3	-0.41	0.15	0.59	0.63	0.75	-0.16	-0.51	-0.51	0.27	0.48	0.51	0.66
Common Stock	-0.05	-0.04	0.06	0.03	-0.15	-0.05	0.01	-0.15		0.13	-0.07	0.01	0.03	-0.05	0.89	-0.06	-0.7	-0.11	-0.04	-0.66	0.72	-0.1	0.03	0.07	0.06	0.05
Property Plant Equipment	0.7	-0.31	-0.41	-0.75	0.49	0.69	0.29	0.5	0.13		0.44	0.43	0.46	0.15	-0.16	0.61	0.34	0.58	0.78	-0.32	-0.39	0.0	0.39	0.67	0.64	0.72
Short Term Investments	0.78	0.18	0.24	-0.82	0.9	0.79	0.88	0.81	-0.07	0.44		0.89	0.09	0.17	-0.33	0.12	0.62	0.82	0.83	-0.41	-0.38	-0.3	0.11	0.62	0.65	0.8
Long Term Debt	0.75	0.03	0.37	-0.77	0.95	0.75	0.96	0.64	0.01	0.43	0.89		-0.08	0.24	-0.22	0.03	0.6	0.83	0.78	-0.47	-0.21	-0.17	-0.08	0.55	0.58	0.75
Short Term Debt	0.56	0.15	-0.9	-0.27	0.03	0.57	-0.1	0.26	0.03	0.46	0.09	-0.08		-0.07	-0.14	0.89	0.07	-0.14	0.38	-0.22	-0.17	-0.09	0.99	0.71	0.68	0.4
Current Deferred Revenue	0.16	-0.19	0.1	-0.19	0.31	0.16	0.2	0.3	-0.05	0.15	0.17	0.24	-0.07		-0.13	-0.12	0.22	0.15	0.18	-0.19	-0.16	-0.25	-0.1	0.0	0.01	0.17
Intangible Assets	-0.35	0.08	0.14	0.38	-0.39	-0.33	-0.16	-0.41	0.89	-0.16	-0.33	-0.22	-0.14	-0.13		-0.24	-0.76	-0.39	-0.39	-0.36	0.81	-0.08	-0.1	-0.22	-0.22	-0.3
Net Tangible Assets	0.66	0.01	-0.9	-0.36	0.18	0.65	-0.03	0.15	-0.06	0.61	0.12	0.03	0.89	-0.12	-0.24		0.19	0.06	0.48	-0.21	-0.32	0.23	0.86	0.75	0.71	0.47
Good Will	0.59	0.04	0.04	-0.57	0.73	0.59	0.57	0.59	-0.7	0.34	0.62	0.6	0.07	0.22	-0.76	0.19		0.61	0.59	0.23	-0.78	-0.03	0.07	0.44	0.46	0.5
Long Term Debt Total	0.64	-0.32	0.3	-0.88	0.85	0.62	0.71	0.63	-0.11	0.58	0.82	0.83	-0.14	0.15	-0.39	0.06	0.61		0.84	-0.37	-0.47	0.13	-0.19	0.44	0.44	0.79
Capital Surpluse	0.9	-0.23	-0.15	-0.98	0.82	0.89	0.65	0.75	-0.04	0.78	0.83	0.78	0.38	0.18	-0.39	0.48	0.59	0.84		-0.51	-0.47	-0.03	0.32	0.78	0.78	0.97
Deferred Long Term Liab	-0.47	0.22	0.0	0.5	-0.37	-0.46	-0.4	-0.16	-0.66	-0.32	-0.41	-0.47	-0.22	-0.19	-0.36	-0.21	0.23	-0.37	-0.51		-0.35	-0.07	-0.17	-0.49	-0.47	-0.63
Treasury Stock	-0.39	0.14	0.22	0.46	-0.45	-0.38	-0.14	-0.51	0.72	-0.39	-0.38	-0.21	-0.17	-0.16	0.81	-0.32	-0.78	-0.47	-0.47	-0.35		-0.13	-0.14	-0.25	-0.25	-0.36
Long Term Investments	-0.08	-0.48	-0.17	0.03	-0.08	-0.12	-0.27	-0.51	-0.1	0.0	-0.3	-0.17	-0.09	-0.25	-0.08	0.23	-0.03	0.13	-0.03	-0.07	-0.13		-0.17	-0.06	-0.11	-0.01
Short Long Term Debt	0.55	0.28	-0.87	-0.2	0.03	0.56	-0.07	0.27	0.03	0.39	0.11	-0.08	0.99	-0.1	-0.1	0.86	0.07	-0.19	0.32	-0.17	-0.14	-0.17		0.69	0.68	0.34
Net Invested Capital	0.92	0.15	-0.49	-0.69	0.61	0.92	0.52	0.48	0.07	0.67	0.62	0.55	0.71	0.0	-0.22	0.75	0.44	0.44	0.78	-0.49	-0.25	-0.06	0.69		1.0	0.81
Net Working Capital	0.92	0.19	-0.45	-0.69	0.62	0.92	0.56	0.51	0.06	0.64	0.65	0.58	0.68	0.01	-0.22	0.71	0.46	0.44	0.78	-0.47	-0.25	-0.11	0.68	1.0		0.8
Capital Stock	0.87	-0.26	-0.15	-0.97	0.76	0.86	0.62	0.66	0.05	0.72	0.8	0.75	0.4	0.17	-0.3	0.47	0.5	0.79	0.97	-0.63	-0.36	-0.01	0.34	0.81	0.8

Click cells to compare fundamentals

About TG Therapeutics Financial Statements

TG Therapeutics investors use historical fundamental indicators, such as TG Therapeutics' Capital Stock, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in TG Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Capital Stock	156 K	146.1 K
Issuance Of Capital Stock	41.7 M	39.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for TGTX Stock Analysis

When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

TGTX Capital Stock from 2010 to 2025

Latest TG Therapeutics' Capital Stock Growth Pattern

TGTX Capital Stock Regression Statistics

TGTX Capital Stock History

Other Fundumenentals of TG Therapeutics

TG Therapeutics Capital Stock component correlations

About TG Therapeutics Financial Statements

Also Currently Popular

Additional Tools for TGTX Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY